查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1845679

2024 年至 2031 年精神药物市场（按药物类型、用途、最终用户和地区划分）

Psychotropic Drugs Market By Drug Type, Application, End-Users, & Region for 2024-2031
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

精神药物市场评估 - 2024-2031

2024 年精神药物市场规模估计为 203 亿美元，预计到 2031 年将扩大到 276.8 亿美元，2024 年至 2031 年的复合年增长率为 4.7%。市场估值的上升证实了精神药物在治疗精神健康障碍的重要性，并显示全球医疗保健系统对药物介入的依赖程度日益加深。

精神药市场定义/概述

精神药物是指能够改变情绪、知觉或行为的化学物质。精神药物用于治疗多种精神疾病，包括忧郁症、焦虑症、躁郁症和思觉失调症。这些药物透过影响大脑中神经传导物质的水平发挥作用，而神经传导物质是调节情绪和思考过程的化学信使。虽然精神药物可能会引起副作用，但它们能够改善症状，帮助患者管理心理健康，带来显着益处。精神药物的益处不仅限于减轻症状，还可以提高生活品质、改善社交功能并提升整体幸福感。

全球精神药物市场概况

受精神疾病患者数量不断增加等因素的影响，精神药物市场蓬勃发展。癫痫相关问题，例如行为异常、怪异动作和癫痫发作、情绪波动，甚至意识丧失，在已开发国家和开发中国家的居民中普遍存在。由于生活方式的压抑和人们日常生活的差异，精神健康问题的数量正在增加。经济困难、持续患病、创伤经历、脑损伤以及严重酗酒和吸毒也增加了精神疾病的可能性。大多数因上述问题而患有精神疾病的人都没有得到适当的照顾。

因此，市场成长更加迅速。许多生产商正专注于以创新方式将精神药物用于新的应用。精神药物主要用于治疗癫痫、失智症、恐慌症、创伤后压力症候群、忧郁症、情绪性精神障碍、失智症、恐慌症和强迫症。大多数因上述问题而患有精神疾病的人没有得到适当的治疗。因此，市场正在迅速扩张。许多製造商正专注于以创新方式将精神药物用于新的应用。癫痫、失智症、恐慌症、创伤后压力症候群、忧郁症、情绪性精神障碍、忧郁症症和强迫症是精神药物用于治疗的一些最常见的疾病。

哪些因素推动了精神药物市场的成长？

全球对精神疾病的认识和认知度不断提高，大大促进了市场扩张。随着社会对精神健康态度的不断转变，精神药物作为各种精神疾病的有效治疗方式正逐渐被接受。此外，医学研究和技术的进步在推动市场成长方面发挥关键作用。药物研发的持续创新，例如新剂型和给药方法的引入，正在提高精神药物的疗效和耐受性。旨在寻找新的治疗标靶和改进现有药物的临床试验正在进行中，这进一步推动了市场扩张。

忧郁症、焦虑症、躁郁症和思觉失调症等精神疾病的盛行率不断上升，刺激了对精神药物的需求。都市化、生活方式的改变和压力水平的上升等因素正在全球增加这些疾病的发病率，刺激了精神药物的服用。此外，老年人口的成长，特别是在已开发地区，正在推动市场成长。由于与老龄化相关的变化、慢性健康状况和社会孤立，老年人更容易患有精神疾病，这需要使用精神药物来控制症状和改善生活品质。新兴国家对精神药物的接受度不断提高，为市场扩张开闢了新的途径。这些地区的快速都市化和经济发展使医疗保健专业人员和患者采用药物干预治疗精神疾病的意愿增强，从而推动了市场成长。此外，旨在改善精神健康保健基础设施和可近性的有利政府措施和政策正在推动市场扩张。不断上涨的医疗成本，加上减少精神疾病耻辱感的努力，使得患者更容易获得精神药物，进一步推动了市场成长。

哪些因素导致精神药市场销售下降？

监管挑战和审查力度的加强对市场动态产生了不利影响。精神药物处方和配药方面的监管日益严格，加上候选药物的核准流程愈发严格，这些因素正在限制市场成长。人们对精神药物安全性和副作用的担忧日益加剧，降低了消费者信心，导致销售额下降。关于成瘾、成瘾性和长期健康风险等副作用的报告提高了患者和医疗保健提供者的认知度，导致对这些药物的需求下降。

此外，替代治疗方法和精神疾病治疗方法的出现对精神药物市场构成了竞争威胁。心理治疗、认知行为疗法、正念介入和生活方式改变等非药理学的处置方法正逐渐成为传统药物的有效治疗方法，并逐渐蚕食精神药物的市场份额。

全球医疗保健系统面临成本上升和资源有限等问题，这导致支付方采取削减成本的措施，并限制精神药物的报销。这导致患者获得精神药物的机会减少，销售量下降。此外，学名药竞争加剧和专利到期也导致品牌精神药物销售下降。

专利到期会降低市场独占性，使非专利药製造商得以凭藉低成本替代品进入市场，从而降低品牌药的市场份额和整体销售。围绕精神健康和精神药物的负面认知和社会污名阻碍了患者寻求治疗和坚持服用处方药。对误解或评判的恐惧可能导致患者避免或停止服用精神药物，从而导致精神药物的销售和使用率下降。

目录

第一章全球精神药物市场简介

  • 市场定义
  • 市场区隔
  • 调查时间表
  • 先决条件
  • 限制

第二章：已验证的市场调查方法

  • 资料探勘
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程
  • 业界专家的重要见解
  • 资料来源

第三章执行摘要

  • 市场概况
  • 生态测绘
  • 绝对的商机
  • 市场吸引力
  • 全球精神药物市场区域分析
  • 全球精神药物市场（按药物类型划分）（百万美元）
  • 全球精神药物市场按分销管道划分（百万美元）
  • 未来市场机会
  • 全球市场区隔
  • 产品生命线

第四章：全球精神药物市场展望

  • 世界各地精神药物的演变
  • 驱动程式
    • 司机1
    • 司机2
  • 阻碍因素
    • 阻碍因素1
    • 阻碍因素2
  • 机会
    • 机会 1
    • 机会 2
  • 波特五力模型
  • 价值链分析
  • 定价分析
  • 宏观经济分析

第五章全球精神药物市场（依药物类型）

  • 概述
  • 止痛药
  • 麻醉剂
  • 抗精神病药物（AP）
  • 抗忧郁症（AD）
  • 其他的

6. 全球精神药物市场按分销管道划分

  • 概述
  • 医院药房
  • 零售药局
  • 网路药局
  • 其他的

7. 全球精神药物市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

第八章：全球精神药品市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要进展
  • 公司地理分布
  • 公司产业足迹
  • ACE矩阵

第九章：公司简介

  • ABB
  • Ely Lilly and Company
  • Forest Laboratories
  • Mylan NV
  • Randox Laboratories Ltd.
  • FUJIFILM Wako Pure Chemical Corporation

第 10 章：经过验证的市场情报

  • 关于已验证的市场情报
  • 动态资料视觉化
简介目录
Product Code: 80574

Psychotropic Drugs Market Valuation - 2024-2031

In 2024, the psychotropic drugs market was estimated at USD 20.3 Billion, with a projected increase to USD 27.68 Billion by 2031, at a CAGR of 4.7% from 2024 to 2031, reflecting sustained expansion within the sector. The upward trajectory observed in market valuation underscores the significance of psychotropic drugs in addressing mental health disorders, indicative of a growing reliance on pharmaceutical interventions within healthcare systems worldwide.

Psychotropic Drugs Market: Definition/Overview

Psychotropic drugs are defined as chemical substances that alter mood, perception, and behavior. They are prescribed to treat a wide range of mental health conditions, including depression, anxiety, bipolar disorder, and schizophrenia. These medications work by influencing the levels of neurotransmitters in the brain, which are chemical messengers that regulate mood and thought processes. While psychotropic drugs can cause side effects, they offer significant advantages by improving symptoms and enabling individuals to manage their mental health. Their benefits extend beyond symptom reduction, potentially leading to increased quality of life, improved social functioning, and better overall well-being.

Global Psychotropic Drugs Market Overview

The Psychotropic Drugs Market has grown quickly as a result of factors including the rising number of people suffering from mental disease. Epilepsy-related issues, such as abnormalities, strange behavior or seizures, feelings, and even loss of awareness, have become more prevalent among residents of industrialized and developing nations. The number of mental issues has grown as a result of a pressured existence and differences in routine between people. Also contributing to an increased likelihood of mental illness include issues with money, continuing medical ailments, traumatic experiences, brain injury, and severe alcohol and drug use. Most individuals with mental illnesses brought on by the aforementioned issues do not receive the proper care.

As a result, the market grows more rapidly. Many producers are concentrating on new ways to employ psychiatric medications in additional applications. Psychotropic medications are mostly used to treat epilepsy, dementia, panic disorder, post-traumatic stress disorder, depressive disorders, affective disorders, dementia, panic attacks, and obsessive-compulsive disorder. The majority of people who suffer from mental diseases brought on by the aforementioned problems do not get the correct care. As a result, the market expands quickly. Many manufacturers are focusing on innovative methods to use psychiatric drugs in new contexts. Epilepsy, dementia, panic disorder, post-traumatic stress disorder, depressive disorders, affective disorders, panic attacks, and obsessive-compulsive disorder are among the most common conditions that psychotropic drugs are used to treat.

What Factors are Driving the Growth of the Psychotropic Drugs Market?

Increasing awareness and recognition of mental health disorders worldwide are contributing significantly to the expansion of the market. As societal attitudes toward mental health continue to evolve, there is a growing acceptance of psychotropic medications as effective treatment options for various psychiatric conditions. Moreover, the advancements in medical research and technology are playing a pivotal role in driving market growth. Continuous innovations in drug development, including the introduction of novel formulations and delivery methods, are enhancing the efficacy and tolerability of psychotropic drugs. Ongoing clinical trials aimed at identifying new therapeutic targets and improving existing medications are further fueling market expansion.

The rising prevalence of mental health disorders, such as depression, anxiety, bipolar disorder, and schizophrenia, is amplifying the demand for psychotropic medications. Factors such as urbanization, changing lifestyles, and increasing stress levels are contributing to the escalating incidence of these conditions globally, thereby driving the uptake of psychotropic drugs. Furthermore, expanding geriatric population demographics, particularly in developed regions, are bolstering market growth. Older adults are more susceptible to mental health disorders due to age-related changes, chronic health conditions, and social isolation, thereby necessitating the use of psychotropic medications for symptom management and improved quality of life. The growing acceptance of psychotropic drugs in emerging economies is opening up new avenues for market expansion. As these regions undergo rapid urbanization and economic development, there is a greater willingness among healthcare providers and patients to adopt pharmacological interventions for mental health treatment, thereby propelling market growth. Additionally, favorable government initiatives and policies aimed at improving mental healthcare infrastructure and accessibility are driving market expansion. Increased healthcare spending, coupled with initiatives to reduce the stigma associated with mental illness, are facilitating greater patient access to psychotropic medications, thereby fostering market growth.

What Factors are Plummeting Sales of the Psychotropic Drugs Market?

The regulatory challenges and increased scrutiny from regulatory agencies are impacting market dynamics negatively. Heightened regulations regarding the prescribing and dispensing of psychotropic medications, coupled with stringent approval processes for new drug candidates, are constraining market growth. Growing concerns over the safety and side effects associated with psychotropic drugs are dampening consumer confidence and leading to a decline in sales. Reports of adverse reactions, including dependency, addiction, and long-term health risks, have raised awareness among patients and healthcare providers, resulting in reduced demand for these medications.

Additionally, the emergence of alternative treatment modalities and therapies for mental health disorders is posing a competitive threat to the psychotropic drugs market. Non-pharmacological approaches such as psychotherapy, cognitive-behavioral therapy, mindfulness-based interventions, and lifestyle modifications are gaining traction as effective alternatives to traditional medication-based treatments, thereby diverting market share away from psychotropic drugs.

Healthcare systems globally are grappling with escalating costs and limited resources, prompting payers to adopt cost-cutting measures and reimbursement restrictions for psychotropic medications. This has led to reduced access to these drugs for patients, resulting in declining sales volumes. Moreover, increasing generic competition and patent expirations are contributing to the decline in sales of branded psychotropic medications.

As patents expire, market exclusivity diminishes, allowing generic manufacturers to enter the market with lower-priced alternatives, thereby eroding the market share of branded drugs and driving down overall sales revenue. The negative perceptions and social stigma surrounding mental health and psychotropic medications are deterring some individuals from seeking treatment and adhering to prescribed medication regimens. Misconceptions and fear of judgment may lead patients to avoid or discontinue psychotropic medications, thereby resulting in decreased sales and utilization of these drugs.

Category-Wise Acumens

Which Drug Type Category Holds the Dominant Market Share in the Psychotropic Drugs Market?

The dominant market share in the psychotropic drugs market is held by antipsychotics. Antipsychotics are widely prescribed medications used to manage various psychotic disorders, including schizophrenia, bipolar disorder, and certain types of depression. They work by modulating neurotransmitter activity in the brain to alleviate symptoms such as hallucinations, delusions, and disorganized thinking. Antipsychotics are characterized by their ability to target specific receptors in the brain, such as dopamine and serotonin receptors, to regulate neurotransmitter signaling pathways. This mechanism of action helps to restore neurochemical balance and improve cognitive function in individuals with psychotic disorders.

Furthermore, the market dominance of antipsychotics is reinforced by the diverse range of formulations available, including oral tablets, injections, and long-acting depot formulations. These different administration routes cater to the varying needs and preferences of patients and healthcare providers, thereby enhancing market penetration and patient adherence to treatment regimens.

The sustained market leadership of antipsychotics can be attributed to their established efficacy and safety profile, supported by extensive clinical research and real-world evidence. Despite concerns about side effects such as weight gain, metabolic disturbances, and extrapyramidal symptoms, antipsychotics remain the cornerstone of pharmacological treatment for psychotic disorders due to their demonstrated effectiveness in managing symptoms and preventing relapse.

Additionally, the market dominance of antipsychotics is perpetuated by the presence of both branded and generic versions of these medications. While branded antipsychotics command higher prices and offer additional features such as extended-release formulations and novel delivery systems, generic alternatives provide cost-effective options for patients and healthcare systems, thereby ensuring broad accessibility and affordability. The continuous innovation and development of novel antipsychotic agents with improved efficacy, tolerability, and safety profiles are expected to further consolidate the market position of this drug category. Emerging research into targeted therapies and personalized medicine approaches holds promise for advancing the treatment of psychotic disorders and sustaining the dominance of antipsychotics in the psychotropic drugs market.

Is the Depression Segment Poised to Emerge as the Primary Focal Point Within the Psychotropic Drugs Market?

Depression, a prevalent mental health disorder characterized by persistent feelings of sadness, hopelessness, and loss of interest, is garnering increased attention as a significant public health concern globally. The growing recognition of depression as a leading cause of disability and impaired quality of life is driving heightened demand for effective treatment options, thereby propelling the growth of the depression segment within the psychotropic drugs market. As societal awareness of mental health issues continues to evolve, there is a greater acceptance of pharmacological interventions for managing depression, including antidepressant medications.

Advancements in medical research and drug development are contributing to the expansion of the depression segment within the psychotropic drugs market. Continuous innovation in antidepressant therapies, including the introduction of novel mechanisms of action and formulations, is enhancing treatment outcomes and patient adherence. Additionally, ongoing clinical trials aimed at identifying biomarkers for depression and developing personalized treatment approaches are further bolstering the prominence of this segment.

The rising prevalence of depression worldwide, attributed to factors such as socioeconomic stressors, lifestyle changes, and demographic shifts, is fueling demand for psychotropic medications targeted at alleviating depressive symptoms. As the burden of depression continues to escalate, healthcare providers are increasingly turning to pharmacotherapy as a primary treatment modality, thus driving market growth within the depression segment. Furthermore, the evolving landscape of mental healthcare delivery, characterized by increased integration of primary care and mental health services, is facilitating greater access to antidepressant medications for individuals with depression. Collaborative care models and telemedicine platforms are expanding patient reach and streamlining the delivery of psychotropic drugs, thereby amplifying the significance of the depression segment within the market.

The favorable government policies and initiatives aimed at addressing mental health disparities and improving access to treatment are creating a conducive environment for market expansion within the depression segment. Increased funding for mental health programs, coupled with efforts to reduce stigma and raise awareness, are fostering greater acceptance and utilization of psychotropic medications for depression management.

In conclusion, the depression segment is poised to emerge as the primary focal point within the psychotropic drugs market, driven by factors such as growing recognition of depression as a public health concern, advancements in drug development, rising prevalence of depression, evolving healthcare delivery models, and supportive government policies.

Country/Region Wise Acumens

Could North America Drive an Increase in Sales within the Psychotropic Drugs Market?

With its substantial share of the global pharmaceutical market and advanced healthcare infrastructure, North America is poised to exert a significant influence on sales growth in this sector. The region, encompassing the United States and Canada, boasts high levels of healthcare expenditure and a robust pharmaceutical industry, positioning it as a key player in driving market expansion. North America's sizable patient population and strong demand for mental health treatments further underscore its potential to drive increased sales within the psychotropic drugs market.

As awareness of mental health issues continues to grow, there is a greater acceptance of pharmacological interventions for managing psychiatric disorders, thus fueling demand for psychotropic medications. The region's well-established healthcare system and regulatory framework provide a conducive environment for pharmaceutical companies to introduce and commercialize psychotropic drugs. Stringent regulatory standards ensure product safety and efficacy, instilling confidence among healthcare providers and patients and facilitating market penetration and sales growth.

Moreover, the rising prevalence of mental health disorders in North America, including depression, anxiety, and bipolar disorder, contributes to the escalating demand for psychotropic medications. Factors such as changing societal attitudes toward mental health and improved diagnosis and treatment rates further drive sales within the market. Ongoing research and development activities focused on novel drug formulations, therapeutic targets, and personalized medicine approaches are expected to stimulate further sales growth in North America. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations foster innovation and the introduction of new treatment options, expanding the market opportunity for psychotropic drugs. Favorable reimbursement policies and extensive healthcare coverage for mental health treatments in many North American jurisdictions enhance patient access to psychotropic medications, driving sales within the market. Government initiatives aimed at improving mental health awareness and reducing stigma further support market expansion efforts.

Will the Sales of the Psychotropic Drugs Market fare well in Europe?

Europe, characterized by diverse nations with varying healthcare systems and regulatory frameworks, is expected to witness positive sales performance in this sector. With its significant market size and increasing awareness of mental health issues, Europe is poised to be a favorable market for psychotropic medications. The region's large and aging population contributes to the growing demand for mental health treatments, thus driving sales within the psychotropic drugs market. As the prevalence of mental health disorders such as depression, anxiety, and bipolar disorder continues to rise across Europe, there is a heightened need for effective pharmacological interventions to address these conditions. Europe benefits from a well-established healthcare infrastructure and access to quality mental healthcare services. The presence of specialized psychiatric hospitals, mental health clinics, and community-based support systems ensures comprehensive care for individuals with mental health needs, thereby contributing to the uptake of psychotropic medications and supporting sales growth within the market.

The region's commitment to research and innovation in healthcare fosters the development of new psychotropic drugs and treatment modalities. Ongoing advancements in drug discovery, clinical trials, and personalized medicine approaches are expected to drive further sales growth in the region. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations facilitate innovation and the introduction of new treatment options, expanding the market opportunity for psychotropic drugs. Additionally, favorable reimbursement policies and healthcare coverage for mental health treatments in many European countries enhance patient access to psychotropic medications, thus supporting sales growth within the market. Government initiatives aimed at improving mental health awareness, reducing stigma, and integrating mental health services into primary care settings further bolster market prospects. The regulatory harmonization efforts within the European Union ensure consistent standards for drug approval and market access across member states, facilitating the introduction and commercialization of psychotropic drugs. This regulatory alignment streamlines market entry processes for pharmaceutical companies and promotes innovation in the psychotropic drugs market.

Competitive Landscape

Analyzing the competitive landscape of the psychotropic drugs market is crucial for gaining insights into the industry's dynamics. This research explores the competitive landscape, focusing on key players, market trends, innovations, and strategies. This analysis will provide valuable insights to industry stakeholders, assisting them in adeptly navigating the competitive environment and seizing emerging opportunities. Understanding the competitive landscape will enable stakeholders to make informed decisions, align with market trends, and formulate strategies to strengthen their market position and competitiveness in the psychotropic drugs market.

Some of the prominent players operating in the psychotropic drugs market include:

Pfizer Inc.

Ely Lilly & Company

Forest Laboratories

Mylan N.V.

Randox Laboratories Ltd.

FUJIFILM Wako Pure Chemical Corporation

Psychotropic Drugs Market Latest Developments

In May 2023, the acceptance of the supplementary New Drug Application for REXULTI(R) for the treatment of agitation associated with dementia caused by Alzheimer's disease was announced by Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Lundbeck LLC. REXULTI, the first and only pharmaceutical therapy licensed in the United States for agitation linked with dementia caused by Alzheimer's disease, was the subject of this announcement. Agitation, a prevalent neuropsychiatric symptom of Alzheimer's dementia and one of the most difficult and stressful elements of caring for persons with the disease, has been documented in almost half of persons with Alzheimer's disease.

In June 2021, the FDA approval for the treatment of adults with schizophrenia and adults with bipolar I disorder as a maintenance monotherapy or as an acute treatment for manic or mixed episodes monotherapy or as an adjunct to lithium or valproate was announced for LYBALVI by Alkermes Plc. LYBALVI, an oral, once-daily atypical antipsychotic drug composed of the novel chemical compound sami-orphan and the well-known antipsychotic olanzapine, was the focus of this announcement.

Psychotropic Drugs Market, By Category

  • Drug Type:
  • Antidepressants
  • Antipsychotics
  • Anxiolytics
  • Mood Stabilizers
  • Stimulants
  • Sedative-Hypnotics
  • Application:
  • Depression
  • Schizophrenia
  • Bipolar Disorder
  • Anxiety Disorders
  • Attention-Deficit Hyperactivity Disorder
  • Insomnia
  • End-Users:
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PSYCHOTROPIC DRUGS MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Psychotropic Drugs Market Geographical Analysis (CAGR %)
  • 3.6 Global Psychotropic Drugs Market, By Drug Type (USD Million)
  • 3.7 Global Psychotropic Drugs Market, By Distribution Channel (USD Million)
  • 3.8 Future Market Opportunities
  • 3.9 Global Market Split
  • 3.10 Product Life Line

4 GLOBAL PSYCHOTROPIC DRUGS MARKET OUTLOOK

  • 4.1 Global Psychotropic Drugs Evolution
  • 4.2 Drivers
    • 4.2.1 Driver 1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint 1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity 1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL PSYCHOTROPIC DRUGS MARKET, BY DRUG TYPE

  • 5.1 Overview
  • 5.2 Analgesics
  • 5.3 Anesthetics
  • 5.4 Anti-psychotics (AP)
  • 5.5 Antidepressants (AD)
  • 5.6 Others

6 GLOBAL PSYCHOTROPIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
  • 6.2 Hospital Pharmacies
  • 6.3 Retail Pharmacies
  • 6.4 Online Pharmacies
  • 6.5 Others

7 GLOBAL PSYCHOTROPIC DRUGS MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Argentina
    • 7.5.3 Rest of Latin America
  • 7.6 Middle-East and Africa
    • 7.6.1 UAE
    • 7.6.2 Saudi Arabia
    • 7.6.3 South Africa
    • 7.6.4 Rest of Middle-East and Africa

8 GLOBAL PSYCHOTROPIC DRUGS MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Developments
  • 8.4 Company Regional Footprint
  • 8.5 Company Industry Footprint
  • 8.6 ACE Matrix

9 COMPANY PROFILES

  • 9.1 ABB
    • 9.1.1 Company Overview
    • 9.1.2 Company Insights
    • 9.1.3 Product Benchmarking
    • 9.1.4 Key Developments
    • 9.1.5 Winning Imperatives
    • 9.1.6 Current Focus & Strategies
    • 9.1.7 Threat from Competition
    • 9.1.8 SWOT Analysis
  • 9.2 Ely Lilly and Company
    • 9.2.1 Company Overview
    • 9.2.2 Company Insights
    • 9.2.3 Product Benchmarking
    • 9.2.4 Key Developments
    • 9.2.5 Winning Imperatives
    • 9.2.6 Current Focus & Strategies
    • 9.2.7 Threat from Competition
    • 9.2.8 SWOT Analysis
  • 9.3 Forest Laboratories
    • 9.3.1 Company Overview
    • 9.3.2 Company Insights
    • 9.3.3 Product Benchmarking
    • 9.3.4 Key Developments
    • 9.3.5 Winning Imperatives
    • 9.3.6 Current Focus & Strategies
    • 9.3.7 Threat from Competition
    • 9.3.8 SWOT Analysis
  • 9.4 Mylan N.V.
    • 9.4.1 Company Overview
    • 9.4.2 Company Insights
    • 9.4.3 Product Benchmarking
    • 9.4.4 Key Developments
    • 9.4.5 Winning Imperatives
    • 9.4.6 Current Focus & Strategies
    • 9.4.7 Threat from Competition
    • 9.4.8 SWOT Analysis
  • 9.5 Randox Laboratories Ltd.
    • 9.5.1 Company Overview
    • 9.5.2 Company Insights
    • 9.5.3 Product Benchmarking
    • 9.5.4 Key Developments
    • 9.5.5 Winning Imperatives
    • 9.5.6 Current Focus & Strategies
    • 9.5.7 Threat from Competition
    • 9.5.8 SWOT Analysis
  • 9.6 FUJIFILM Wako Pure Chemical Corporation
    • 9.6.1 Company Overview
    • 9.6.2 Company Insights
    • 9.6.3 Product Benchmarking
    • 9.6.4 Key Developments
    • 9.6.5 Winning Imperatives
    • 9.6.6 Current Focus & Strategies
    • 9.6.7 Threat from Competition
    • 9.6.8 SWOT Analysis

10 VERIFIED MARKET INTELLIGENCE

  • 10.1 About Verified Market Intelligence
  • 10.2 Dynamic Data Visualization